general interest

Striving for efficiency in workflow is not a new concept. Automation and use of smart technologies in industries such as automotive and shipping, and services like USPS and UPS, have drastically changed the way they function today not just with innovation but with personalization. Pharma is beginning to understand the need for adopting personalized workflow as well. Now, what can Pharma learn from these industries and how can it apply it to the industry?

In this multi-part series on assessing the health of your cells, we review different factors to be considered in your assessments such as cell viability, proliferation, apoptosis, and autophagy. The first part covers the methods for assessing viability and proliferation and their advantages, and discusses some common considerations.

Striking a balance between encouraging innovation and allowing access to knowledge is not simple. Allowing patents for modifications of naturally occurring organisms and cells pose a particular challenge to the scientific community. Adding to the complexity is the variations in regulations between countries. This article discusses these issues with specific examples in biotechnology and biomedical fields.

How can we easily identify biomarkers for different immune cell types? Refer to this color-coded poster for quick and simple identification of human lineage biomarkers.

How are educational curricula developed? Who sets the standards? How do companies that develop science education kits keep up with this and design their kits around the curricula? Find out in this article.

In 2015, we published an extensive array of tips, protocols, videos, articles of general interest, customer testimonials, and technical and application notes on bioradiations.com. Here is a list of the most popular 2015 stories.

What is so noble about receiving an award? What if it is an Ig Nobel award? This article reviews what Ig Nobel awards are, how they are determined, and discusses some research topics that were awarded the Ig Nobel awards this year.

Academic labs don’t have the money to do full-scale validations of antibodies. What tricks can small biotechs teach them about validation? Find out.

From using nonspecific polyclonal antibodies to developing monoclonal antibodies from immortalized antibody-producing cells to antibody engineering and generation of antibodies using an animal-free library with billions of antibody fragments to choose from, the antibody technology has seen tremendous advances. Explore where this journey started and what the current trends are and what the human combinatorial antibody library (HuCAL) technology destination has to offer!

Few discoveries have changed the pace of discovery and the types of questions we can ask as drastically and quickly as CRISPR-based genome editing. But where did CRISPR come from? How was it adapted to become such a game-changing genome editing tool? And why are some of its greatest proponents alarmed?